Share-based Payment Arrangement, Expense of Context Therapeutics Inc. from 30 Jun 2021 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Context Therapeutics Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2021 to 30 Sep 2025.
  • Context Therapeutics Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $323,081, a 52% increase year-over-year.
  • Context Therapeutics Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $1,237,733, a 43% increase year-over-year.
  • Context Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2024 was $841,867, a 22% decline from 2023.
  • Context Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2023 was $1,076,865, a 10% increase from 2022.
  • Context Therapeutics Inc. annual Share-based Payment Arrangement, Expense for 2022 was $976,440, a 104% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Context Therapeutics Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $1,237,733 $323,081 +$110,079 +52% 01 Jul 2025 30 Sep 2025 10-Q 05 Nov 2025 2025 Q3
Q2 2025 $1,127,654 $389,114 +$232,077 +148% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $895,577 $293,717 +$53,710 +22% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025 2025 Q1
Q4 2024 $841,867 $231,821 -$24,230 -9.5% 01 Oct 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
Q3 2024 $866,097 $213,002 -$41,947 -16% 01 Jul 2024 30 Sep 2024 10-Q 05 Nov 2025 2025 Q3
Q2 2024 $908,044 $157,037 -$126,066 -45% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $1,034,110 $240,007 -$42,755 -15% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025 2025 Q1
Q4 2023 $1,076,865 $256,051 +$12,414 +5.1% 01 Oct 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
Q3 2023 $1,064,451 $254,949 -$21,572 -7.8% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $1,086,023 $283,103 +$41,779 +17% 01 Apr 2023 30 Jun 2023 10-Q 07 Aug 2024 2024 Q2
Q1 2023 $1,044,244 $282,762 +$67,804 +32% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $976,440 $243,637 01 Oct 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $276,521 +$125,446 +83% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $241,324 +$132,854 +122% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $214,958 01 Jan 2022 31 Mar 2022 10-Q 10 May 2023 2023 Q1
Q3 2021 $151,075 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2022 2022 Q3
Q2 2021 $108,470 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2

Context Therapeutics Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $841,867 -$234,998 -22% 01 Jan 2024 31 Dec 2024 10-K 20 Mar 2025 2024 FY
2023 $1,076,865 +$100,425 +10% 01 Jan 2023 31 Dec 2023 10-K 20 Mar 2025 2024 FY
2022 $976,440 +$498,580 +104% 01 Jan 2022 31 Dec 2022 10-K 21 Mar 2024 2023 FY
2021 $477,860 01 Jan 2021 31 Dec 2021 10-K 22 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.